Investment Rating - The report maintains a "Buy" rating for the company [8] Core Insights - The company reported a revenue of 499 million RMB for 1H25, representing an 812% year-over-year increase, driven by strong sales of Supacizumab in the AD field and unique indications in the nasal area [1][2] - The company plans to participate in the 2025 medical insurance negotiations, which is expected to enhance drug accessibility [1] - The early pipeline shows significant global potential, with CMG901 expected to report results in 2026 and CM512 anticipated to release AD clinical data in 2H25 [1][4] Summary by Sections Sales Performance - Supacizumab sales reached approximately 169 million RMB in 1H25, with expectations for continued growth due to its efficacy advantages over competitors and the upcoming allergy season [2] - The company is preparing to launch an injection pen formulation, which is expected to enhance convenience for patients [2] Early Pipeline Development - CM512 is positioned as a potential treatment for multiple indications, including AD and asthma, with ongoing clinical trials showing promise [3] - The company has clear upcoming milestones for CMG901, with a global Phase III trial for gastric cancer expected to report results in 2026 [4] Financial Health - The company reported a net loss of 78.8 million RMB in 1H25, a 77% reduction in losses year-over-year, with cash reserves of approximately 2.796 billion RMB [5] - The company plans to invest around 300 million RMB in capital expenditures for capacity expansion [5] Profitability Forecast - The revenue forecast for 2025 is adjusted to 727 million RMB, with net profit estimates for 2025 and 2026 at -742 million RMB and -604 million RMB, respectively [6][12] - The target price based on DCF valuation is set at 90.89 HKD, reflecting an increase from the previous estimate of 56.05 HKD [6][12]

证券研究报告 中国东方教育 (667 HK) 港股通 上调全年盈利预测，维持"买入" 考虑到公司新招生强劲，规模效应和严格控费下利润率快速提升，我们上调 25-27 年经调整净利润至 8.08/10.36/12.99 亿元（上调 26%/34%/39%）， 考虑到 25 年已过半，我们切换到 26 年估值，考虑到公司利润弹性大，给 予 20x 26E PE（可比公司 Wind 一致预期均值 13.67x），得到目标价 10.30 港元（前值：6.47 港元，对应 20x 25E PE），维持"买入"评级。 风险提示：在校生人数增长不及我们预期；区域中心建设进展缓慢或效益不 及规划预期；公办职校分流及竞争加剧。 利润弹性如期兑现，上调全年预期 2025 年 8 月 28 日│中国香港 职业教育 公司公布 25H1 业绩：收入 21.86 亿元，yoy+10.2%；净利润 4.03 亿元， yoy+48.4%，符合业绩预告（yoy+45%~50%）；经调整净利润 4.16 亿元， yoy+49.5%。利润的增长主要得益于新招生的增长以及高效的运营及成本费 用控制。公司积极适配市场需求，持续优化专业结构和补足学历教 ...

Investment Rating - The investment rating for the company is "Buy" [7] Core Views - The company reported a strong growth in new business value (NBV) for life insurance, with a year-on-year increase of 63% in 1H25, driven by significant growth in both agency and bancassurance channels [3] - The property insurance segment showed improved underwriting performance, with a combined ratio (COR) decreasing by 1.4 percentage points to 94.8%, leading to a substantial increase in underwriting profit by 44.6% [2] - The total investment return increased by 40.2% year-on-year, with an annualized total investment yield rising by 0.9 percentage points to 5.0%, contributing to profit growth [4] - The company has adjusted its earnings per share (EPS) forecasts for 2025, 2026, and 2027 to RMB 1.02, RMB 1.14, and RMB 1.24 respectively, based on improved performance in property insurance and investment [5] Summary by Sections Property Insurance - The property insurance segment's COR improved due to a 3.1 percentage point decrease in expense ratio, despite a 1.7 percentage point increase in loss ratio [2] - Insurance service revenue for property insurance grew by 5.6% year-on-year, with motor and non-motor insurance increasing by 3.5% and 8.9% respectively [2] - The net profit from property insurance increased by 35% year-on-year, supported by strong premium growth and improved underwriting performance [2] Life Insurance - The life insurance segment's NBV growth was primarily driven by bancassurance, which saw an 81% increase, accounting for 35% of total NBV [3] - The overall new policy premium for the life insurance segment grew by 15.4% year-on-year, indicating resilience in the agency channel [3] - Despite the strong growth in NBV, the profit from life insurance decreased by 13% due to rising service expense ratios [3] Investment Performance - The company capitalized on favorable market conditions, resulting in a significant increase in total investment income and a higher annualized investment yield [4] - The asset allocation strategy included an increase in equity investments, with the stock allocation rising by 1.7 percentage points to 5.4% [4] Earnings Forecast and Valuation - The target price for the company's A/H shares has been raised to RMB 9.3 and HKD 7.0, reflecting the positive adjustments in EPS forecasts [5] - The projected gross premium income for 2025 is estimated at RMB 572.06 billion, with a growth rate of 6.39% [21]

Investment Rating - The investment rating for the company is "Buy" [8][6]. Core Views - The company reported a steady growth in New Business Value (NBV) of 20% year-on-year for 1H25, despite a decline in pre-tax profit by 11.5% [2][6]. - The interim dividend increased by 19% to RMB 0.24, outpacing profit growth [1]. - The annualized net investment return decreased to 2.78%, while the total investment return fell to 3.29% [4]. Summary by Sections Financial Performance - The earnings per share (EPS) for 1H25 was RMB 1.45, a 6.9% increase year-on-year, primarily due to a significant reduction in income tax expenses [1]. - The NBV for 1H25 showed a 20% increase on a comparable basis, indicating robust growth compared to peers [2]. - The company’s net assets increased by 2.8% year-to-date, and the embedded value (EV) rose by 5.5% [5]. Business Segments - The individual insurance channel saw a 22% decline in new premiums, influenced by regulatory changes, but the NBV from this channel grew by 9.5% [2]. - The bancassurance channel experienced a remarkable 111% increase in new premiums, contributing significantly to the overall NBV growth [2]. Investment Strategy - The asset allocation shifted with a decrease in fixed-income assets and an increase in equity investments, reflecting a strategic response to market conditions [4]. - The total investment assets grew by 7.8% since the beginning of the year [4]. Future Outlook - The company anticipates a 17.9% growth in NBV for 2025, supported by a recovery in the bancassurance channel following regulatory changes [2][6]. - The projected EPS for 2025 is adjusted to RMB 3.20, with subsequent years also showing growth [6][12]. Valuation - The target price for the A/H shares has been raised to RMB 49 and HKD 26, respectively, based on a discounted cash flow (DCF) valuation method [6][12].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.80 [1][10]. Core Insights - The company reported a significant improvement in underwriting performance, with a 32.3% year-on-year increase in net profit for 1H25, reaching RMB 24.454 billion [6]. - The combined ratio (COR) decreased by 1.4 percentage points to 94.8%, primarily due to a reduction in expense ratio [6]. - The company expects continued growth in both the auto and non-auto insurance segments, with projected increases in premium income and improvements in underwriting profitability [7][8]. Summary by Sections Financial Performance - In 1H25, the company achieved a net profit of RMB 24.454 billion, reflecting a 32.3% increase year-on-year [6]. - The total investment income for 2025 is projected to be RMB 28.056 billion, with a year-on-year growth of 0.63% [5]. - The expected earnings per share (EPS) for 2025 is RMB 1.86, with a projected growth of 28.89% compared to 2024 [10]. Auto Insurance Segment - The auto insurance premium income rose by 3.4% to RMB 144.065 billion in 1H25, with a COR of 94.2%, down 2.2 percentage points year-on-year [7]. - The company reported a significant increase in premium income from new energy vehicle insurance, which grew by 38.4% year-on-year [7]. Non-Auto Insurance Segment - Non-auto insurance service income increased by 8.9% year-on-year, with a COR of 95.7% [8]. - The company anticipates a 9.2% growth in non-auto insurance service income for 2025, with a projected COR of 98.6% [8]. Investment Performance - The total investment income increased by 26.6% year-on-year, with a non-annualized total investment return of 2.6% [9]. - The return on equity (ROE) for 1H25 improved to 9.0%, with expectations to reach 15% in 2025 [9]. Valuation and Forecast - The target price has been adjusted to HKD 19.80 based on improved earnings forecasts for 2025, 2026, and 2027 [10]. - The company’s price-to-earnings (PE) ratio is projected to decrease from 11.49 in 2024 to 8.91 in 2025 [5].

上 市 公 司 医药生物 2025 年 08 月 28 日 石药集团 (01093) ——上半年业绩基本符合预期，创新管线持续投入 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 08 月 27 日 | | --- | --- | | 收盘价（港币） | 9.72 | | 恒生中国企业指数 | 9020.26 | | 52 周最高/最低（港币） | 11.13/4.27 | | H 股市值（亿港币） | 1,119.93 | | 流通 H 股（百万股） | 11,521.95 | | 汇率（人民币/港币） | 1.0953 | 一年内股价与基准指数对比走势： -10% 40% 90% 140% 190% HSCEI 石药集团 《 CSPC Pharmaceutical Group Limited(01093): Expecting BD opportunities of innovative pipelines 》 2025/05/30 证券分析师 周文远 A0230518110003 zhouwy@swsresearch.com 研究支持 胡梦婷 A0230524060004 ...

上 市 公 司 交通运输 2025 年 08 月 28 日 深圳国际 (00152) ——关注物流园转型升级项目进展，高股息具备吸引力 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 08 月 27 日 | | --- | --- | | 收盘价（港币） | 7.58 | | 恒生中国企业指数 | 9020.26 | | 52 周最高/最低（港币） | 8.26/5.68 | | H 股市值（亿港币） | 185.24 | | 流通 H 股（百万股） | 2,443.74 | | 汇率（人民币/港币） | 1.0953 | 一年内股价与基准指数对比走势： -5% 15% 35% 55% HSCEI 深圳国际 资料来源：Bloomberg 相关研究 《深圳国际（00152）深度： 国企优质资 源禀赋，物流园转型升级带来业绩弹性 》 2025/06/21 证券分析师 闫海 A0230519010004 yanhai@swsresearch.com 研究支持 郑逸欢 A0230124010001 zhengyh@swsresearch.com 联系人 郑逸欢 (8621)2329781 ...

战略转型期短期承压，回购计划规模吸引 事件：联易融科技发布 2025 年中期业绩，2025H1 公司实现收入 37.5 亿元（人 民币，下同），同比下降 9.3%；毛利率从 2024H1 的 70.9%降至 56.0%，降幅 14.9 个百分点，主要原因是收入结构的变化与市场竞争所致。25H1 归母净亏损 38.0 亿元，同比扩大 57.7%；经调整亏损（非国际财务报告准则）37.2 亿元，同 比大幅扩大 97.4%，主要系对历史过桥供应链资产计提减值准备增加（减值损失 27.0 亿元，同比增 66.5%）及业务结构调整所致。公司公告称在未来 12 个月使 用不低于 8000 万美元（约合 6.23 亿港元，按最近收市市值为总股本比例约 11%） 进行回购，回购计划力度较大，股东回报有较大亮点。 互联网与软件服务 | 投资评级： | | | 买入 | | --- | --- | --- | --- | | | | 维持 | 评级 | | 6 | 个月目标价 | 3.45 | 港元 | | 股价 | 2025-8-28 | 2.76 | 港元 | 报告摘要 多极流转云成增长主力，AMS云短期承压。核心企业云作为 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 120.34 [7][5] Core Insights - The new P7 model was officially launched on August 27, 2025, with a price range of HKD 219,800 to HKD 301,800, and it is expected to significantly boost monthly sales to over 40,000 units from September to December 2025 [2][3] - The company is focusing on a three-pronged strategy involving range extension, smart technology, and robotics, which is anticipated to drive incremental growth [1][5] - The partnership with Volkswagen has deepened, with a strategic agreement signed to expand the development of electronic and electrical architecture, which is expected to enhance revenue opportunities [3][5] Summary by Sections New Product Launch - The new P7 features an 800V high-voltage SiC platform, 5C supercharging AI battery, and a maximum range of 820 km, with a powerful performance of 593 Ps and 0-100 km/h acceleration in 3.7 seconds [2][3] - The design and interior of the P7 are aimed at attracting younger consumers who appreciate performance and innovative design [2] Growth Catalysts - The company plans to launch the X9 range extender version in Q4 2025, which is expected to have a significant competitive advantage with a range of 450 km [3] - The introduction of the VLA model for the P7 and G7 is set to enhance the company's smart technology capabilities, with plans for L4 autonomous vehicles by 2026 [3] Robotics Development - The IRON humanoid robot, designed with 62 degrees of freedom and advanced AI capabilities, has entered factory training and is expected to be showcased at the "Xiaopeng 1024 Technology Day" in 2025 [4][5] Financial Projections - Revenue forecasts for 2025-2027 are set at RMB 85.606 billion, RMB 127.626 billion, and RMB 153.919 billion respectively, with a projected return to profitability in Q4 2025 [5][10] - The report maintains a valuation of 2.1x 2025E PS for the sales business, reflecting a premium over comparable companies [5][14]

[Table_StockNameRptType] 快手-W（01024） 港股公司点评 可灵商业化持续推进，首次宣派特别股息 | 投资评级：买入（维持） [Table_Rank] | | --- | | 报告日期： 2025-08-28 | | [Table_BaseData] 收盘价（港元） | 76.00 | | --- | --- | | 近 12 个月最高/最低（港元）81.65/37.75 | | | 总股本（百万股） | 4,316 | | 流通股本（百万股） | 3,588 | | 流通股比例（%） | 100.00 | | 总市值（亿港元） | 3,280 | | 流通市值（亿港元） | 2,727 | [公司价格与恒生指数走势比较 Table_Chart] -16% 15% 46% 77% 108% 8/24 11/24 2/25 5/25 快手-W 恒生指数 [Table_Author] 分析师：金荣 执业证书号：S0010521080002 邮箱：jinrong@hazq.com [Table_CompanyReport] 相关报告 1.快手 25Q1 业绩点评：可灵商业化进 程加速，业 ...